InvestorsHub Logo
Followers 0
Posts 40
Boards Moderated 0
Alias Born 07/16/2019

Re: None

Wednesday, 11/20/2019 3:27:44 PM

Wednesday, November 20, 2019 3:27:44 PM

Post# of 54984
"FDA spokesman Michael Felberbaum said the omission from the so-called unified agenda does not mean the FDA will stop working on it. He said the agency is reviewing comments it received in response to the proposal to cap nicotine levels in cigarettes."

https://www.cnbc.com/2019/11/20/tobacco-stocks-rise-on-report-that-fda-wont-cut-nicotine-levels-in-cigarettes.html

I never owned this name on the expectation for the NPRM but people need to calm down. The FDA has no commissioner in place at the moment and they received over 7700 statements during the public comment period. They're also receiving a tremendous amount of flak over the Ecig debacle when it comes to youth adoption rates. MRTP and PMTA are still on track. VLN mandate might get back on schedule in 2020. Regardless, I am bullish on XXII and seriously increased my position today. The new commissioner's background is oncology. Ring a bell? VLN is coming and there is a serious market for it without the VLN mandate. Consumer surveys say as much. Research the size of the smoking cessation market in the US and you'll realize that the play here has always been getting a VLN product to market first. The VLN mandate should not be anyone's base-line scenario for seeing upside potential in XXII.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent XXII News